Document ID: chunk:federal_register_of_legislation:F2023C00456:schedule:2
Version: federal_register_of_legislation:F2023C00456
Segment Type: schedule
Provision Reference: sch 2
Character Range: 112340–113369

Schedule 2

Specified ingredient names

Part 1—Dual labelling name permitted from 1 May 2023 until 30 April 2026

Ingredient name
 amobarbital (amylobarbitone)
 amphotericin B (amphotericin)
 asparaginase (colaspase)
 calcitonin salmon (salcatonin)
 dactinomycin (actinomycin D)
 doxycycline hyclate (hydrochloride)
 estropipate (piperazine oestrone)
 formoterol (eformoterol)
 furosemide (frusemide)
 glycopyrronium bromide (glycopyrrolate)
 lidocaine (lignocaine)
 mecobalamin (co-methylcobalamin)
 pentoxifylline (oxpentifylline)
 phenobarbital (phenobarbitone)
 procaine benzylpenicillin (procaine penicillin)
 tetracosactide (tetracosactrin)

Part 2—Dual labelling name permitted from 1 May 2025 until 30 April 2028

Ingredient name
 dosulepin (dothiepin)
 hydroxycarbamide (hydroxyurea)
 tetracaine (amethocaine)
 trihexyphenidyl (benzhexol)

Part 3—Dual labelling name

Ingredient name
 alimemazine (trimeprazine)
 mercaptamine (cysteamine)
 Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain)